Lilly(Eli) & Company (LLY) Dividends

For an income investor, Eli Lilly's dividend presents a paradox of safety versus sufficiency. The dividend payout ratio based on the provided EPS of $22.95 is a very conservative 25%, which indicates strong sustainability from an earnings perspective. The company has a history of growing its dividend. However, the current yield of 0.62% is well below the broader market and typical sector averages, offering negligible income. More critically, the free cash flow picture is weak. A FCF yield of 1.0% suggests the company generates minimal free cash flow relative to its enormous market capitalization. This raises questions about the robustness of cash coverage for the dividend, as a high FCF conversion rate is a key Quality Indicator. The framework looks for FCF margins >10-15% and high conversion; Lilly's metrics do not meet this standard. The capital is instead being deployed for immense reinvestment, evidenced by a stellar ROE of 77.8% and revenue growth of 42.6%. The balance sheet, with a Debt/Equity of 1.6, shows leverage that is manageable for a pharmaceutical giant but not the substantial net cash position preferred for ultra-safe dividends. In essence, Lilly is a capital compounder, not an income vehicle. The dividend is a token, while virtually all profits are reinvested to fuel growth, which the market is richly rewarding. Analysis based on data as of 2024-05-15.